Introduction
▼ Opioid dependence is a major health and social issue [ 1 , 2 ] and is associated with an excess rate of somatic and psychiatric complications including HIV, hepatitis, depression, suicidality and antisocial behaviour [ 1 , 3 , 4 ] . Approximately 200 000 persons in Germany have a risky use of illicit substances, excluding cannabis use [ 5 ] . Although the number of drug-related deaths continues to decrease still 1 237 persons died in 2010 because of drug use, most of them because of heroin overdose (42.8 %), 12.5 % of the deaths were related to methadone/levo-methadone alone or in combination with other drugs and 0.5 % were related to buprenorphine alone or in combination with other drugs [ 5 ] .
were registered as currently in maintenance treatment with d/lmethadone (58 %), levo-methadone (23 %), buprenorphine (19 %) and other substitution drugs including diamorphine (0.3 %) [ 7 , 11 ] . Both treatments with full opioid agonists (e. g., methadone) and partial agonist/antagonist (buprenorphine) have been found to be eff ective in reducing substance use and improving somatic, psychiatric as well as social functioning [ 2 , 12 -14 ] . However the increasing level of diversion [ 8 , 15 , 16 ] and the risk of fatal outcomes in opioid maintenance treatment have raised concerns about safety issues in the treatment of opioid dependence. The combination of the partial mu-agonist/kappa-antagonist buprenorphine with the full mu-antagonist naloxone in a ratio of 4:1 was developed to improve treatment outcomes and to reduce the risk of diversion [ 17 , 18 ] . When the combination is administered sublingually as prescribed, naloxone is inactive because of its low sublingual bioavailability [ 19 ] and only the eff ects of buprenorphine are experienced [ 16 , 20 ] blocking most of the mu-receptors [ 12 ] . But when the medication is administered parenterally (intravenous or nasal) the eff ects of naloxone are experienced for the fi rst 15-90 min [ 21 ] . Both buprenorphine and naloxone have a very high bioavailability but naloxone binds more rapidly to the opioid mu-receptors than buprenorphine causing precipitated withdrawal if the user has full agonists in the body [ 16 , 18 ] . Thus the combination of buprenorphine with naloxone is expected to reduce the risk of intravenous or nasal misuse [ 19 ] . The combination minimizes the risk of opioid overdose and diversion by making it unattractive for selling [ 17 , 21 ] because of the unpleasant experience directly after parenteral abuse [ 18 , 21 ] . In addition the potential pleasurable eff ects of buprenorphine are diminished due to the smaller and delayed agonist eff ects after the subsiding antagonistic eff ect of naloxone [ 21 ] . While a number of randomized clinical trials [ 2 , 12 , 17 , 22 ] demonstrated the overall effi cacy of buprenorphine-naloxone in the treatment of opioid dependence, to date no non-interventional observational studies on the eff ectiveness and safety of the novel buprenorphine-naloxone combination refl ecting "real world" conditions with a profound and comprehensive assessment both for physicians and patients have been published. Such studies are essential to verify clinical trial results and to receive reliable safety data from routine care treatment. The study was designed to collect comprehensive safety and eff ectiveness data on a large patient sample in offi ce-based routine opioid drug dependence treatment with buprenorphine-naloxone over a 12-month period (2008-2010) .
Methods

▼
Study goals
The primary objectives of the non-interventional study was to describe the retention rate of patients pre-treated with buprenorphine, methadone, levo-methadone or another maintenance drug after 12 months of treatment with buprenorphinenaloxone under real-life conditions and to collect comprehensive safety data during switch to and treatment with buprenorphinenaloxone. The secondary objectives were to describe the switch to the new medication in terms of dosing, mode of prescription and subjective eff ects. Data on eff ectiveness, acceptance and tolerance of opioid dependence treatment with buprenorphine-naloxone should be examined regarding met and unmet needs.
Study design
The study was a nationwide, prospective 12-month observational, non-interventional, post-authorization safety study (PASS) with patients currently in drug dependence treatment with another medication such as d/l-methadone, levo-methadone or buprenorphine for whom a switch to buprenorphinenaloxone was indicated and planned ( • ▶ Fig. 1 ). A comprehensive paper-based clinical research form was used for data capture. The study was part of the Risk Management Plan (RMP) for the newly marketed product buprenorphine-naloxone (Suboxone ® ) and therefore a requirement of the European Medicine Agency (EMA). The study is registered with the National Institute of Health (NIH) at ClinicalTrials.gov (NCT00723749).
Study population
From N = 69 physicians working in addiction medicine and qualifi ed pursuant to German Controlled Substances Regulation (Betäubungsmittelverordnung, BtMVV) § 5 (2) (1) (6) and with authorization granted by the Association of Statutory Health Insurance Physicians (Kassenärztliche Vereinigung, KV) N = 384 opioid-dependent patients were enrolled (total population). All patients over 15 years of age who had consented to opioid drug dependence treatment within the scope of medical, social and psychotherapeutic measures, for whom the switch to buprenorphine-naloxone was indicated and planned and who had signed the informed consent form could be included. The participating physicians were not subject to directives in terms of the use of buprenorphine-naloxone and prescribed the medication in the form of a conventional, commercially available product. Therapeutic indications and contraindications for opioid dependence treatment according to the Summary of Product Characterization (SmPC) for buprenorphine-naloxone and national treat- ment guidelines had to be observed when selecting patients for participation in the non-interventional study. Of this total population n = 47 datasets were excluded from the fi nal analysis. Reasons were treatment not started (only baseline documentation available, n = 18), missing fi nal documentation (month 12 or drop-out, n = 21) and incomplete documentation (no documentation of induction phase and follow-up documentation, n = 8). The fi nal analysis population of n = 337 eligible datasets contains all patients with written informed consent, as approved by the ethics committee of the Ludwig-Maximilian University in Munich, as well as complete study documentation for at least baseline (day 0), start of treatment with buprenorphinenaloxone (day 1) and the fi nal documentation either as end-ofobservation (month 12) or drop-out documentation. For n = 3 patients day 1 documentation was missing and documentation of day 2 of treatment with buprenorphine-naloxone was used instead.
Assessments
Physicians questionnaire (third-party assessment)
The treating physicians informed eligible patients about the purpose of the study, the data collection procedure and the data privacy protection. Only after agreeing to all aspects and signing the informed consent form the baseline assessment, which was conducted before switching the patient to buprenorphinenaloxone, could be commenced. The physician's questionnaire for evaluation of the patients was a paper-based assessment tool specially developed for the noninterventional study with 45 pages including 12 sections with several standardized instruments to document the following patient parameters: socio-demographics, substance use history, treatment history, co-morbidities, co-medication, concomitant drug use, urine drug screening, main reason for switch to buprenorphine-naloxone, treatment with buprenorphinenaloxone, premature discontinuation before end of observation, eff ectiveness measures with modifi ed Clinical Global Impression (mCGI), Objective Opiate Withdrawal Scale (OOWS), and safety. It was the physician's decision which treatment data were transferred from the patient's medical chart to the questionnaire. The CGI [ 23 ] is a standard measure for global assessments of illness consisting of 3 diff erent global measures. In the study a modifi cation of the Clinical Global Impression Severity scale (CGI-S) and a modifi cation of the Clinical Global Impression Improvement scale (CGI-I) was used. The OOWS [ 24 ] is a standardized scale for measuring the physically observable signs of opiate withdrawal for rating by the physician. All adverse events (non-serious and serious including adverse drug reactions and pregnancies) were listed as they were spontaneously reported and documented at each visit by the treating physician.
Patients questionnaires (self assessment)
During the 12-month observational period all patients were asked to complete 4 standardized questionnaires in accordance with the schedule of observation points ( • ▶ Fig. 2 ): 1) Short Form 36 -Health Survey (SF-36) [ 25 ] , a 36-item self-assessment questionnaire to survey the current health status with 2 modifi ed indication specifi c questions in reference to drug dependence; 2) Subjective Opiate Withdrawal Scale (SOWS) [ 24 ] , the subjective counterpart of the OOWS is a standardized scale for measuring the intensity of symptoms of opiate withdrawal from the perspective of the patient; 3) revised psychiatric Symptom Check-List (SCL-90R) [ 26 , 27 ] , a standardized self-assessment tool to measure subjective impairment due to somatic and psychiatric symptoms; 4) visual analogue scale for craving (VAS Craving), an instrument specially invented for the non-interventional study by the fi rst author containing twelve 100-mm visual analogue scales for the substances alcohol, cannabis, amphetamines, hallucinogens, cocaine, barbiturates, benzodiazepines, opiates, d/l-methadone/levo-methadone, buprenorphine, codeine/DHC and other. Patients were asked to visualize their current craving for each of the listed substances.
Assessment schedule
To ensure eligible and valid data collection for comprehensive evaluation of induction and course of drug dependence treatment with buprenorphine-naloxone compared to baseline data before switch to the new medication, physician's and patient's questionnaires were scheduled for specifi c time points of observation ( • ▶ Fig. 2 ).
Statistics and analysis
Except for socio-demographics, retention rate, regular end of treatment and safety all comparisons were made between baseline (day 0) and fi nal assessment as regular end of observation (month 12) or premature discontinuation documentation (drop- out) for the total sample as well as for the analysis groups. Analyses concerning treatment with buprenorphine-naloxone used day 1/start of treatment as baseline measures. Single and multinomial logistic regression and chi-square tests were used for descriptive correlations between the defi ned analysis groups, start and end of observation. For numerical parameters, sample statistics, mean and standard deviation, minimum and maximum were calculated. For categorical data, absolute and relative frequencies were calculated. Data generated repeatedly in the course of time were evaluated per observation point. The diff erences between baseline and fi nal assessment are shown for specifi c numerical data as absolute and relative diff erence. Retention rates were estimated using Kaplan-Meier method and are presented as survival curves and 12-month survival estimates. The options "not tested" and "no test" were set to missing values. For the option "no change" the status from the previous visit was carried forward. Statistical signifi cance was defi ned as p-values < 0.05. Statistical analysis was done with STATA/SE 9 [ 28 ] .
Method
Points of observation
Measures and specifi cations
Retention rate: percentage of patients still in drug dependence treatment with buprenorphine-naloxone at the end of the observation period or who completed treatment after achieving a successful therapeutic outcome (regular end of treatment/ abstinence).
Safety: percentage of all documented non-serious and serious adverse events including adverse drug reactions, which were coded using MedDRA version 11.1 [ 29 ] .
Eff ectiveness: improvement of scores from the standardized instruments mCGI for general health, SCL-90R for mental health, OOWS and SOWS for withdrawal; regular end of treatment (patient abstinent) documented by the treating physician in the fi nal assessment as premature discontinuation documentation was defi ned as positive treatment outcome and patients were counted as completers.
Quality of life (QoL): improvement of scores from the standardized instrument SF-36 comparing baseline with the fi nal assessment.
Acceptance and tolerance: reduction of concomitant drug use measured by urine drug screening, craving for illicit substances measured by the standardized instrument VAS craving and number of fresh needle marks.
Analysis groups (post-hoc generation)
Completers: patients still in drug dependence treatment with buprenorphine-naloxone at the end of observation (month 12) including patients with dropout reason regular end of treatment (patient abstinent from all illegal drugs including opiate-substitution).
Non-completers: patients with documented premature discontinuation of treatment with buprenorphine-naloxone for any reason other than regular end of treatment (patient abstinent).
Pre-treated: patients with documented current maintenance pharmacotherapy at baseline. Untreated: patients without any documented previous maintenance pharmacotherapy at baseline [patients with no current maintenance treatment at study entry, but with a history of previous substitution treatment(s) are excluded from analysis between pre-treated and untreated patients].
Buprenorphine: patients in treatment with the mono compound buprenorphine at baseline.
(Levo-)methadone: patients in treatment with d/l-methadone or levo-methadone at baseline.
The term analysis groups refers to the above defi ned groups of completer/non-completer, pre-treated/untreated and buprenorphine/(levo-)methadone.
Results
▼
Data from N = 337 eligible patients was examined.
Patient population
Socio-demographics • ▶ Table 1 summarizes patient characteristics at baseline for the total sample and all analysis groups. Most of the patients were male and in their mid-thirties, ranging from 18-62 years, and German nationality. Completers were older, married or living with a partner, working in a full-time job and living in their own fl at. Higher rates of the more unfavourable characteristics such as unemployment, being divorced or single and being homeless are found in the group of non-completers.
Addiction history
As shown in • ▶ Table 1 N = 244 patients were in maintenance treatment with buprenorphine (66.4 %), d/l-methadone (20.9 %), levo-methadone (9.8 %) or another maintenance drug (2.9 %) at baseline. For n = 49 patients the treatment with buprenorphinenaloxone was their fi rst opioid drug dependence treatment and n = 44 patients were previously but not at baseline in maintenance treatment. Most of the participating patients had a long opioid addiction history from almost 14 years on average, ranging from 4 months to 50 years. Patients switched from the mono-compound buprenorphine and pre-treated patients had a signifi cantly longer drug addiction history [patients with no current maintenance treatment at study entry, but with a history of previous substitution treatment(s) are excluded from analysis between pre-treated and untreated patients]. Almost all patients used opioids in their life (94.6 %) with no difference within the analysis groups. Non-completers revealed signifi cantly higher rates in the use of benzodiazepines (72.7 % vs. 56.5 % completer, p = 0.003), cocaine (85.5 % vs. 64.9 %, p ≤ 0.001), amphetamines (67.2 % vs. 36.8 %, p ≤ 0.001), hallucinogens (42.5 % vs. 25.8 %, p = 0.002), codeine (36.1 % vs. 18.8 %, p = 0.001), barbiturates (29.0 % vs. 11.2 %, p ≤ 0.001). Pre-treated patients revealed signifi cantly higher rates in the use of cocaine (75.4 % vs. 59.6 % untreated, p = 0.039), benzodiazepines (64.2 % vs. 47.9 %, p = 0.035) and codeine (27.4 % vs. 10.9 %, p = 0.018). Signifi cantly higher rates of life-time cannabis use were found in the group of patients switched from buprenorphine [91.9 % vs. 79.7 % (levo-)methadone, p = 0.008].
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Retention rate and drop-out Retention rate
Of the total eligible patients n = 181 were still in treatment at the end of observation after 12 months of treatment with buprenorphine-naloxone and n = 14 patients terminated their treatment during the observation period because they were rated as abstinent by their treating physician. The 12-month retention rate, analyzed with Kaplan-Meier estimator, was 57.1 % for the total analysis population ( • ▶ Fig. 3 ). There were no diff erences between pre-treated and untreated patients ( • ▶ Fig. 3 ). A slightly higher retention rate was found in (levo-)methadone patients ( • ▶ Fig. 4 ).
Reasons for dropout N = 142 patient terminated treatment before end of observation. The most frequently documented reasons for drop out were "lost to follow up" (16.7 %), "concomitant drug use/relapse" (12.2 %), "side eff ects" (12.2 %) and "non-compliance/disciplinary reasons" (10.9 %). Signifi cantly more untreated patients (16.7 % vs. 4.6 % pretreated, p = 0.033) were rated as abstinent by the treating physician.
No deaths occurred during the entire observational period. Only n = 1 hospitalization and n = 3 pregnancies led to premature termination of treatment with buprenorphine-naloxone.
Safety
Safety reporting for non-interventional studies is done according to regulations for routine care practice in Germany. The research forms of this study contained special sheets for documentation of all adverse events and the physician's folder provided reporting forms for serious adverse events but it was the physician's decision if an incident during the observation period required documentation and reporting, respectively. Therefore only non-serious and serious adverse events documented and reported by the treating physician could be included in the analysis. In this paper the adverse events reported were evaluated for the analysis population only.
Serious adverse events (SAE)
For n = 4 (1.2 %) of the patients from the analysis population (N = 337) there were n = 4 serious adverse events reported during the complete observational period including 30 days post-study time. The events, listed as system organ class and the term reported by the treating physician (in brackets) were n = 1 psychiatric disorder (hospitalization because of suspected adjustment disorder), n = 1 social circumstances (concomitant drug use), n = 1 surgical and medical procedure (stay in hospital) and n = 1 nervous system disorder (epilepsy). One event was reported with certain correlation to the study drug (concomitant drug use), one with likely correlation (hospitalization because of suspected adjustment disorder), one with unlikely correlation (epilepsy) and one with unknown relation to the study drug (stay in hospital). No diff erences within the analysis groups were found in reference to the occurrence of SAEs. No deaths were reported during the study. 
12-Month Retention
Non-serious adverse events (NSAE)
Treatment with buprenorphine-naloxone Reason for switch to buprenorphine-naloxone
The main reasons for switching to buprenorphine-naloxone were long-term maintenance treatment with or without abstinence as fi nal goal (28.8 %), prior maintenance treatment not successful (21.4 %), planned detoxifi cation treatment (17.8 %) and prevention of buprenorphine misuse (17.5 %). For 11.9 % the physicians reported "patient's wish for take home" as reason for the switch to buprenorphine-naloxone.
Dosing of buprenorphine-naloxone
The mean induction dose of buprenorphine-naloxone was 9.2 ± 5.1 mg per day with a maximum of 32.0 mg. This dose slightly increased to 9.6 mg on day 2 and 3 of the treatment with buprenorphine-naloxone and decreased continuously in the course of treatment to 7.7 mg per day. Non-completers received generally higher doses, but those non-completers who were still in treatment at month 6 (n = 37) received virtually the same dose as completers ( • ▶ Fig. 5 ). Patients switched from d/l-methadone or levo-methadone received higher doses of buprenorphine-naloxone than patients switched from the mono-compound buprenorphine ( • ▶ Fig. 6 ). Doses of previous buprenorphine patients did not change during the course of treatment with buprenorphinenaloxone. Interestingly pre-treated and untreated patients' dose of buprenorphine-naloxone did not diff er ( • ▶ Fig. 7 ).
Patients rated as abstinent during the observation period (n = 14)
were not included in the analyses shown above. Their mean induction dose of buprenorphine-naloxone was 8.5 ± 6.3 mg which decreased rapidly to 7.0 ± 4.7 mg at day 7, 4.6 ± 2.6 mg at week 4 and 2.0 ± 1.6 mg at their fi nal assessment.
Mode of prescription
At the induction day most of the patients (87.1 %) received buprenorphine-naloxone on a daily basis at the practice of the treating physician and 8.4 % as take-home prescription. All of the take-home prescriptions were documented for pre-treated patients and signifi cantly more for buprenorphine patients (14.4 % vs. 5.3 % (levo-)methadone, p = 0.043). Take-home prescription increased during treatment with buprenorphine-naloxone and was documented for 25.1 % of the patients at the fi nal assessment. 
Quality of life SF-36
As shown in • ▶ Table 2 the scores of the standardized patient questionnaire SF-36 were relatively low at baseline but increased during treatment with buprenorphine-naloxone signifi cantly for all scales. There was no diff erence between completers and non-completers at baseline except for pain. At the fi nal assessment completers had signifi cantly higher scores in all scales and non-completers revealed no substantial improvement from baseline to fi nal assessment. Pre-treated patients had higher scores at baseline but at the fi nal assessment untreated patients achieved higher scores in all scales of the SF-36 and signifi cantly for the scales emotional well-being and drug dependence compared to pre-treated patients. At baseline buprenorphine patients achieved signifi cantly higher rates compared to (levo-)methadone patients but no diff erence was found at the fi nal assessment. While (levo-)methadone patients improved signifi cantly in all scales, buprenorphine patients showed only for pain, social functioning, emotional role functioning and drug dependence signifi cant improvement from baseline to fi nal assessment.
Eff ectiveness of the treatment with buprenorphinenaloxone
Mental health As shown in • ▶ Table 3 the mean scores of the SCL-90-R at baseline are higher in all scales for non-completers, untreated and (levo-)methadone patients. All patients achieved a signifi cant improvement of psychiatric distress at their fi nal assessment irrespective of analysis group.
Modifi ed Clinical Global Impression -Severity scale (mCGI-S)
• ▶ Fig. 8 shows the modifi ed CGI measuring the general health of the patient from the perspective of the physician. The categories were transformed to numeric scores (0 = very good to 5 = extremely bad). There was no diff erence between completers and non-completers but untreated and (levo-) methadone patients received signifi cantly higher scores at baseline. According to the physicians the general health of all patients improved signifi cantly during treatment with buprenorphine-naloxone except for non-completers. Their general health slightly worsened and the score was signifi cantly higher (p < 0.001) at the fi nal assessment compared to completers.
Withdrawal
SOWS:
The total score of the subjective opiate withdrawal scale at baseline was 17.2 ± 13.5 and decreased to 5.1 ± 8.4 at fi nal assessment. Non-completers achieved a signifi cantly higher score at baseline (19.0 ± 13.6 vs. 15.9 ± 13.4 completers, p = 0.043) and fi nal assessment (11.7 ± 11.7 vs. 3.9 ± 7.0, p < 0.001). Untreated patients (20.8 ± 14.7 vs. 14.9 ± 12.5 pre-treated, p = 0.005) and (levo-) methadone patients (20.3 ± 13.2 vs. 11.8 ± 10.5 buprenorphine, p < 0.001) achieved a signifi cantly higher score at baseline but did not diff er from their comparison group at fi nal assessment. All groups, except non-completer, achieved a signifi cant reduction of subjective opiate withdrawal during the treatment with buprenorphine-naloxone.
OOWS:
The total score of the objective opiate withdrawal scale reported by the treating physicians was 8.8 ± 8.1 at baseline and decreased signifi cantly to 2.2 ± 4.8 (p < 0.001). From the physician's perspective there was no diff erence between completers and non-completers concerning opiate withdrawal at baseline, but at the fi nal assessment non-completers received a significantly higher score (3.8 ± 6.2 vs. 1.1 ± 3.0 completers, p < 0.001). Untreated (12.7 ± 7.4 vs. 7.2 ± 7.6 pre-treated, p < 0.001) and (levo-) methadone (11.1 ± 7.7 vs. 4.9 ± 6.3 buprenorphine, p < 0.001) patients showed signifi cantly more withdrawal symptoms at baseline. At the end of the observation physicians saw no diff erence between untreated and pre-treated patients, but in buprenorphine patients they identifi ed more objective withdrawal symptoms [2.2 ± 4.4 vs. 1.1 ± 3.3 (levo-)methadone, p = 0.050].
Regular end of treatment
For n = 14 patients the premature discontinuation within the 12-month observation period was the regular end of treatment with buprenorphine-naloxone because they were rated as abstinent by their treating physician (4.2 % of the total eligible patient population). Signifi cantly more patients without prior maintenance treatment became abstinent (8.2 % vs. 2.1 % pre-treated, p = 0.002). No diff erence was found between patients with prior buprenorphine treatment and treatment with (levo-)methadone.
Acceptance and tolerance
Concomitant drug use
According to the results of urine drug screenings ( • ▶ Diff . C vs. NC p = 0.895 p = 0.009 p = 0.202 p = 0.002 p = 0.003 p < 0.001 p = 0.585 p = 0.031 p = 0.904 p = 0.003 p = 0.265 p = 0.031 p = 0.120 p < 0.001 p = 0.861 p = 0.001 p = 0.305 p = 0 Diff . PT vs. UT p = 0.052 p = 0.232 p = 0.008 p = 0.676 p < 0.001 p = 0.557 p = 0.014 p = 0.109 p < 0.001 p = 0.088 p < 0.001 p = 0.258 p = 0.183 p = 0.086 p < 0.001 p = 0.028 p = 0.007 p = 0. Diff . B vs. LM p < 0.001 p = 0.602 p < 0.001 p = 0.560 p = 0.029 p = 0.678 p < 0.001 p = 0.531 p < 0.001 p = 0.503 p < 0.001 p = 0.934 p < 0.001 p = 0.882 p < 0.001 p = 0.684 p < 0.001 p = 0.442
Signifi 2.8 (4.6) 4.2 (4.0) 2.2 (3.1) 4.8 (5.7) 2.9 (4.8) p = 0.076 p = 0.008 p = 0.039 p = 0.010 p = 0.345 p = 0.026 p = 0.085 p = 0.003 p = 0.040 p < 0.001 p = 0.094 p = 0.005 p = 0.135 p = 0.006 p = 0.440 p = 0.191 p = 0.078 p = 0.059 Pre-treated 7.8 (8.0) 3.9*** 0.5** (0.9) 4.4 (6.7) 0.5* (1.4) p = 0.137 p = 0.127 p = 0.060 p = 0.090 p = 0.501 p = 0.163 p = 0.053 p = 0.091 p = 106 p = 0.101 p = 0.085 p = 0.118 p = 0.127 p = 0.363 p = 0.312 p = 0.074 p = 0.681 p = 0.127 Buprenorphine 6.6 (6.9) 3.6* (6.0) 6.2 (5.9) 3.2** 2) 2.9*** (5.8) p = 0.006 p = 0.937 p < 0.001 p = 0.507 p = 0.001 p = 0.355 p < 0.001 p = 0.598 p < 0.001 p = 0.547 p < 0.001 p = 0.573 p < 0.001 p = 0.047 p = 0.005 p = 0.320 p < 0.001 p = 0.035 Signifi cance level baseline vs. fi nal assessment shown at the FA-value: * < 0.05; ** < 0.01; *** < 0. 
Fresh needle marks
Physicians documented fresh needle marks for 13.5 % at baseline, for slightly more non-completers (17.3 % vs. 10.8 % completers, p = 0.086) and signifi cantly more untreated patients (20.4 % vs. 9.5 % pre-treated, p = 0.029). Most of these patients had a positive urine drug screening for opioids (75.6 %). At the fi nal assessment physicians reported fresh needle marks for n = 10 patients, all of them were non-completers, n = 4 were pre-treated, n = 2 untreated and n = 4 were switched from buprenorphine. Most of these patients had positive drug screenings for opioids (n = 7). Physicians reported no fresh needle marks for (levo-)methadone patients.
Discussion
▼
The results of this non-interventional study underline the overall eff ectiveness of opioid drug dependence treatment with the 4:1 combination buprenorphine-naloxone. In line with fi ndings in a previous naturalistic study in routine care [ 30 ] the 12-month retention rate of patients induced or switched to buprenorphine-naloxone was 55.7-62.0 % depending on previous maintenance treatment. These rates are also in line with results on retention of patients receiving standard methadone treatment [ 30 -32 ] . No deaths occurred and the very low rate of adverse events emphasizes the high safety profi le of buprenorphinenaloxone. Signifi cant improvements in almost all evaluated domains during the 12-month observation period, irrespective of study completion and previous maintenance treatment, verify the eff ectiveness of the medication found in previous clinical trials [ 2 , 12 , 17 , 19 , 22 ] . As reported by Wittchen et al. 2008 [ 30 ] in their naturalistic study in 2 694 patients, the same proportion of patients (4.2 %) had achieved abstinence during the observational period. Since a certain period (e. g., 5 years) of abstinence is required to reduce the risk of future relapse [ 3 ] we recommend a follow-up study to verify the status of patients with documented regular end of treatment because of abstinence. Compared to international fi ndings on dosing of buprenorphinenaloxone between 16-24 mg/day [ 33 ] , patients observed in this non-interventional study received lower doses of 10 mg/day on average, which decreased to an average of 8 mg/day at the end of the 12-month observation, irrespective of study completion and previous maintenance treatment. Patients switched from d/lmethadone or l-methadone received signifi cantly higher doses of 11 mg/day on average decreasing until end of study to slightly but non-signifi cantly higher doses of approximately 9 mg/day. Dosing is a critical aspect in the treatment and retention of opioid dependent patients -it is important to alleviate the patient's cravings and withdrawal symptoms. The data of this non-interventional study reveal a signifi cant relation between study completion status and withdrawal symptoms as well as opioid craving scores. Non-completers started with signifi cantly higher subjective opiate withdrawal symptoms and craving which was still signifi cantly higher at the time of their premature discontinuation of treatment with buprenorphinenaloxone. According to the physicians there was no diff erence concerning objective opiate withdrawal symptoms between non-completers and completers at baseline, but at the fi nal assessment they reported signifi cantly higher objective withdrawal symptoms for non-completers. Completers achieved a signifi cant reduction of subjective opiate withdrawal during the treatment with buprenorphine-naloxone, however the reduction of craving for opiates was signifi cant for all groups including non-completers compared to baseline. Take-home prescription is an important factor for reintegration into social and occupational life, because it enables the patient to start or stay in employment due to more fl exibility in daily routine. 11.9 % of all eligible patients wanted to switch to buprenorphine-naloxone for take-home prescription. At start of treatment with buprenorphine-naloxone a minority of patients received take-home prescription (8.4 %) and all of these were pre-treated patients. At the end of the observation 25.1 % of all observed patients received take-home prescription. The decision for a take-home prescription is discretionary to the treating physician in compliance with §5 (8) BtMVV (Controlled Substances Prescription Regulation). The patient may receive a takehome prescription for up to 7 consecutive days if the patient is in stable maintenance treatment, without relevant concomitant drug use and use of other substances that interact with the maintenance drug and therefore endanger his health [ 34 ] . Psychiatric comorbidities are very common in this patient population [ 35 ] . At baseline the scores of the SCL-90-R were relatively low with higher rates in all scales for non-completers, untreated patients and (levo-)methadone patients. Apart from non-completers all eligible patients achieved a signifi cant reduction of psychiatric distress at their fi nal assessment. However non-completers did reach lower scores (except for the scale interpersonal sensitivity) at their fi nal assessment. These results are in line with the fi ndings shown by Lieb et al. 2010 [ 35 ] . Opioid dependent patients with high scores in psychiatric distress should receive specifi c care with integrated treatment for both opioid dependence and psychiatric disorder. The scores of the standardized patient questionnaire SF-36 measuring the quality of life in terms of general health, emotional and social functioning were relatively low at baseline but increased signifi cantly during treatment with buprenorphinenaloxone for all scales. At baseline no diff erence between completers and non-completers was found, but at the fi nal assessment completers had signifi cantly higher scores and non-completers revealed no substantial improvement during treatment. These fi ndings suggest that the treatment with buprenorphinenaloxone improves the patient's perception of his emotional and social condition and his ability to reintegrate into a functioning social life. Since non-completers obviously did not benefi t in this domain there might be other infl uencing factors, such as dosing, withdrawal and psychiatric comorbidity that need to be explored in order to support special patient groups in the treatment with buprenorphine-naloxone at an early stage. The results are in line with an Italian longitudinal outpatient survey, which compared the treatment of opioid dependence with buprenorphine-naloxone and methadone [ 32 ] . The retention rate was similar in both groups but signifi cant improvements of social life, educational level and concomitant drug use were found in patients treated with buprenorphine-naloxone. The non-interventional study with buprenorphine-naloxone provides a unique database with comprehensive, reliable and valid data on opioid drug dependence treatment with buprenorphine-naloxone in routine care. However the major limitation is the strict observational nature of the study and the lack of a control group. Confounding factors, which may occur during a non- Table 4 Reduction of drug use during treatment with buprenorphine-naloxone: urine drug screening. interventional study, cannot be controlled in contrast to clinical trials with exact regulations and complete treatment protocol. Thus these uncontrolled confounding factors may infl uence treatment outcomes. All measures used in this paper were of descriptive quality; eff ects and correlations need to be interpreted with caution. Since this observational study was part of the Risk-Management-Plan and based on a commitment to the European Medicine Agency (EMA) after market authorization of the product buprenorphine-naloxone, no control group was planned and necessary. Nevertheless this database with its broad range of variables, standardized assessments and parameters describing the course and outcome of the treatment with buprenorphine-naloxone from the physician's and the patient's perspective allows detailed analyses on safety, somatic and psychiatric health as well as subjective and objective eff ects in reference to special patient groups at diff erent time points. This is the main advantage of this non-interventional study in routine care. In summary, the results indicate high acceptance and tolerance of the treatment accompanied by signifi cant improvements in psychiatric, somatic and social functioning. According to these data buprenorphine-naloxone has an excellent safety profi le also in comparison to methadone with a low risk especially for serious intoxications [ 9 ] . There are increasing safety concerns for intoxications with opioid prescription drugs, with no corresponding European data. Data from surveillance studies like this may help to better estimate the safety risk associated with the use of opioid maintenance treatment. Although only pre-treated patients were the target study population some physicians included a small group of untreated patients and they provided encouraging results. The treatment with buprenorphine-naloxone was highly successful for patients without any experience in maintenance treatment with direct transfer from street heroin use to buprenorphine-naloxone treatment.
Drug use: Urine Drug
The characteristics of non-completers need to be analysed further to identify those at risk for negative outcome. Analyses should focus on identifying ways to retain such patients in treatment and heighten their chances for treatment success.
